Brieflist

Novel approaches to support therapeutic development in ultra-rare cancers

Forecast: not open for applications yet. Dates are the funder's estimate. Save a search and Brieflist marks it when it opens (Grants Pro e-mails you), or get the free weekly digest:

This is a forecast: the funder has announced the grant but applications are not open yet. Dates may change.

The purpose of this program is to support new approaches that can be applied to facilitate therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers.

Read the official page on Grants.gov ↗ Get new grants like this

Funder
Food and Drug Administration (Department of Health and Human Services)
Where
🇺🇸 United States
Status
Forecast
Funding
Not stated
Expected awards
2
Who can apply
Most organisations
Topics
Agriculture & food Justice & security
Opportunity number
FOR-FD-26-004
Instrument
Cooperative agreement

About this grant

The purpose of this program is to support new approaches that can be applied to facilitate therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers.

Specific areas of interest include, but are not limited to, the following examples:

• Development of infrastructure for a coordination network and data repository for patient-level data across institutions and internationally to support drug development and regulatory decision-making for one or more ultra-rare cancers.

• Investigations to explore opportunities to develop and validate early clinical endpoints and other novel efficacy endpoints for evaluation of treatments for ultra-rare cancers.

• Development and implementation of a collaborative multi-stakeholder effort to support generation and use of real-world data leveraging a registry framework for use in development of new therapies for pediatric patients with diffuse midline glioma (DMG) (including diffuse intrinsic pontine glioma, DIPG).

• Innovative approaches to identify new biologically-driven opportunities for clinical development of previously approved drugs or biologics (hereafter referred to as drugs), including drugs for which development has been discontinued, in ultra-rare cancers.

• Research to develop novel approaches to preserve the availability of drugs for which commercial developers have discontinued adult development that have strong potential in ultra-rare cancers but lack financial incentives for commercial development

• Development of methods to incorporate use of telemedicine and/or pragmatic trial design elements (e.g., collecting laboratory and/or imaging data from local facilities) for patient assessments to facilitate enrollment of patients with ultra-rare cancers

• Development of nanoparticle-based delivery approaches for therapeutic nucleic acids targeting onco-fusion transcription factors in metastatic tumor animal models using targeted bioPROTAC degradation or genomic editing strategies. Successful efforts should demonstrate effective delivery and expression in-vivo to tumor cells, and downregulation of the target transcription factor protein while minimizing off-target effects and limiting sequestration of the nanoparticle by the liver, spleen, and lungs.

• Research to exhaustively characterize the plasma-membrane protein expression (surfaceome) of an ultra-rare cancer and the presumed healthy tissue of origin, as well as the resident-tissue stem cells, by single-cell transcriptomics and proteomics. These studies, and available correlative database analyses, should be designed to identify possible combinatorial signatures of plasma membrane proteins unique to the ultra-rare tumor. Tumors of interest include Sclerosing epithelioid fibrosarcoma and atypical teratoid rhabdoid tumors (ATRT).

Eligibility

Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Small businesses; City or township governments; Public and State controlled institutions of higher education; State governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Special district governments; Independent school districts; Public housing authorities/Indian housing authorities; Native American tribal organizations (other than Federally recognized tribal governments); For profit organizations other than small businesses; County governments; Native American tribal governments (Federally recognized)

Applying for grants? Grants Pro e-mails you every morning with the new grants and opened forecasts that match your saved searches, and adds deadline reminders in your calendar, a private RSS feed and CSV export. Try it free for 7 days, then $9/month, cancel any time. See what Pro does →

More from this funder: 12 open opportunities from Food and Drug Administration (FDA).

Applying? Read how to write a winning grant proposal.

Data from Grants.gov, US federal government (public domain). Last checked 19 Nov 2026. Always read the official page before applying: it has the full conditions, documents and how to apply.

Similar grants